Gynecologic, Ovarian, and Cervical Cancer

GYNECOLOGIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Clinical Utility of Deep Phenotyping and Whole-Genome Risk Assessment in Early Cancer Detection and Precision Oncology

State-of-the-art advanced imaging coupled with whole-genome sequencing shows utility in early cancer detection and cancer-associated pathogenic variant detection.
Preclinical Work on Red Blood Cell-Based Therapies in HPV-Positive Solid Tumors Provides Rationale for Clinical Trials in Humans

A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model.
New Research Says There’s No Significant Link Between Talc and Ovarian Cancer, but Some Scientists Push Back Against the Study’s Data and Design

Some experts say the talc study’s data limitations weaken its impact in the field.
Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context

The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer

In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.

GYNECOLOGIC CANCER NEWS

A patient with cancer suffers from insomnia.

Later Bedtime May Be Associated With Higher Levels of Pain in Ovarian Cancer Survivors

May 30, 2020

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alte

Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer

May 30, 2020

The decade-long paradigm shift in decoding ovarian cancer is only now beginning to make its way from

First Study To Report OS Benefit After Secondary Cytoreductive Surgery in Select Patients With Recurrent Ovarian Cancer

May 29, 2020

Treatment advances over recent years render much of the previously used evidence outdated.

Is Etoposide-Methotrexate-Actinomycin D a Preferred Chemotherapy Regimen for Most Patients With High-Risk Gestational Trophoblastic Neoplasms?

May 28, 2020

Researchers compared the immune microenvironments of primary tumors with those at sites of metastase

Study Supports Delaying Cervical Cancer Surgery in COVID-19 Hotspots

May 27, 2020

Next post in Gynecologic Cancer

Researchers compared the immune microenvironments of primary tumors with those at sites of metastase

Study Supports Delaying Cervical Cancer Surgery in COVID-19 Hotspots